Medical Progress

IRVING, TX--(MARKET WIRE)--Nov 12, 2008 -- DelSite, Inc. (OTC BB:DSII.OB - News) today announced that the United States Patent and Trademark Office has granted a Notice of Issuance of patent application No. 10/422,867, titled "High Molecular Weight, Low Methoxyl Pectins and their Production and Uses," relating to the Company's proprietary GelSite® polymer technology. DelSite Biotechnologies, Inc., a subsidiary of DelSite, Inc., is developing and commercializing GelSite® polymer as a controlled-release drug delivery technology for therapeutics and vaccine products.

The issued patent covers the basic composition of the novel plant pectins or polygalacturonic acids (GelSite® polymer), based on its distinct properties that are not found with related natural or synthetic polymers. The claims of this patent are broadly applicable to any use of GelSite® polymer and extend to use in pharmaceutical compositions including proteins, peptides, vaccine antigens and other pharmacological substances.

DelSite has successfully developed the manufacturing process for GelSite® polymer. It is now manufactured under cGMP at a kilogram scale with a purity of > 99%. A Drug Master File for this polymer was filed with the FDA in 2005 and is being updated regularly, allowing streamlined regulatory review for any medical applications.